Open for inclusion

A Phase Ib/II Randomised Open Label Study of BGB324 in Combination With Pembrolizumab or Dabrafenib Compared to Pembrolizumab or Dabrafenib Monotherapy, in Patients With Advanced Non-resectable (Stage IIIc) or Metastatic (Stage IV) Melanoma

Cancer type: Melanoma

Phase: I/II

Principal Investigator: Straume Oddbjørn

Country: NO

Keywords: Norway, Bergen, BGB324, metastatic melonoma

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02872259?term=BGB&rank=6